Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II L19-IL2 plus stereotactic ablative radiotherapy in metastatic NSCLC
2018-002583-11Phase 2Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Feb 2019
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darleukin in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Primary endpoint: Progression-free survival. Started Feb 2019; status: terminated.
02
Drugs
darleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-002583-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002583-11.